Early Trial Of New Drug MK-3475 Promising For Patients With Triple-Negative Breast Cancer
A multi-center, non-randomized phase-Ib clinical trial designed to evaluate the safety, tolerability and antitumor activity of bi-weekly infusions of pembrolizumab (MK-3475, marketed as Keytruda®)…